Detalle Publicación

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Autores: Paiva, Bruno; Puig, N.; Cedena, M. T.; Rosiñol, L.; Cordón, L.; Vidriales, M. B.; Burgos Rodríguez, Leire; Flores-Montero, J.; Sanoja-Flores, L.; Lopez-Anglada, L.; Maldonado, R.; de la Cruz, J.; Gutierrez, N.; Calasanz Abinzano, María José; Martin-Ramos, M. L.; Garcia-Sanz, R.; Martinez-Lopez, J.; Oriol, A.; Blanchard, M. J.; Rios, R.; Martin, J.; Martinez-Martinez, R.; Sureda, A.; Hernandez, M. T.; de la Rubia, J.; Krsnik, I.; Moraleda, J. M.; Palomera, L.; Bargay, J.; Van Dongen, J. J. M.; Orfao, A.; Mateos, M. V.; Blade, J.; San Miguel Izquierdo, Jesús (Autor de correspondencia); Lahuerta, J. J.
ISSN: 0732-183X
Volumen: 38
Número: 8
Páginas: 784 - 792
Fecha de publicación: 2020
PURPOSE: Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine the applicability and sensitivity of the flow MRD-negative criterion defined by the International Myeloma Working Group (IMWG). PATIENTS AND METHODS: In the PETHEMA/GEM2012MENOS65 trial, 458 patients with newly diagnosed MM had longitudinal assessment of MRD after six induction cycles with bortezomib, lenalidomide, and dexamethasone (VRD), autologous transplantation, and two consolidation courses with VRD. MRD was assessed in 1,100 bone marrow samples from 397 patients; the 61 patients without MRD data discontinued treatment during induction and were considered MRD positive for intent-to-treat analysis. The median limit of detection achieved by NGF was 2.9 * 10-6. Patients received maintenance (lenalidomide ± ixazomib) according to the companion PETHEMA/GEM2014MAIN trial.